Evidence map›Paper›PMID 39268467›Full record

ArticleFrontiers in pharmacology2024

AFK-PD alleviated osteoarthritis progression by chondroprotective and anti-inflammatory activity.

Zhuang Qian, Jie Xu, Lei Zhang, Qian Deng, Zhenlin Fan, Xueqiang Guo, Zhuo Liang, Weiyun Wang, Lei Wang, Xiaohua Liao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhuang Qian *Clinical Medical Center of Tissue Engineering and Regeneration, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Xinxiang, China.
Jie Xu *Clinical Medical Center of Tissue Engineering and Regeneration, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Xinxiang, China.
Lei Zhang *Clinical Medical Center of Tissue Engineering and Regeneration, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Xinxiang, China.
Qian DengClinical Medical Center of Tissue Engineering and Regeneration, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Xinxiang, China.
Zhenlin FanClinical Medical Center of Tissue Engineering and Regeneration, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Xinxiang, China.
Xueqiang GuoClinical Medical Center of Tissue Engineering and Regeneration, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Xinxiang, China.
Zhuo LiangClinical Medical Center of Tissue Engineering and Regeneration, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Xinxiang, China.
Weiyun WangClinical Medical Center of Tissue Engineering and Regeneration, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Xinxiang, China.
Lei WangClinical Medical Center of Tissue Engineering and Regeneration, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Xinxiang, China.
Xiaohua LiaoDepartment of Rheumatology and Immunology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Wenjie RenClinical Medical Center of Tissue Engineering and Regeneration, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Xinxiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is the most prevalent cartilage degenerative and low-grade inflammatory disease of the whole joint. However, there are currently no FDA-approved drugs or global regulatory agency-approved treatments OA disease modification. Therefore, it's essential to explore novel effective therapeutic strategies for OA. In our study, we investigated the effects of AFK-PD, a novel pyridone agent, on the development of OA induced by destabilization of the medial meniscus (DMM)

Indexed as

AFK-PDchondrocyteinflammationMAPK/ NF-κB pathwaysosteoarthritis

Identifiers

PMID39268467
PMCPMC11390510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.